Related Experiment Video
Updated: Jul 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Angiotensinogen gene polymorphism as a risk factor for ischemic stroke.
Taizen Nakase1, Toshiki Mizuno, Sanae Harada
1Department of Neurology, Research Institute for Brain and Blood Vessels, 6-10 Senshu Kubota Machi, Akita, Japan 010-0874. nakase@akita-noken.go.jp
Summary
The angiotensinogen (AGT) M allele may increase the risk of lacunar infarction, a type of ischemic stroke, in Japanese men. This genetic risk appears independent of hypertension and other clinical factors.
Area of Science:
- Genetics
- Neurology
- Cardiovascular Science
Background:
- Gene polymorphism for angiotensinogen (AGT) is linked to blood pressure regulation and salt sensitivity.
- The association between AGT gene polymorphism and ischemic stroke risk is debated.
- AGT M235T polymorphism is a specific variant under investigation.
Purpose of the Study:
- To investigate the hypothesis that AGT gene polymorphism is a risk factor for ischemic stroke.
- To examine the relationship between AGT M235T polymorphism and different stroke subtypes.
- To assess potential synergistic effects between AGT polymorphism and clinical risk factors.
Main Methods:
- Case-control study involving 147 stroke patients and 133 healthy controls.
- Analysis of the AGT gene M235T polymorphism in all participants.
- Categorization of stroke patients into four types and two vascular groups.
Main Results:
- The AGT M allele was significantly associated with an increased risk of single lacunar, multiple lacunar, and small arterial lesions in male patients.
- Statistical significance was observed for these associations (p=0.029, 0.031, and 0.026, respectively).
- No synergistic effects were found between AGT gene polymorphism and major clinical risk factors.
Conclusions:
- The AGT M allele may represent an independent risk factor for lacunar infarctions in Japanese men.
- This genetic predisposition to lacunar stroke is not influenced by hypertension.
- Further research may elucidate the precise mechanisms linking AGT polymorphism to specific stroke types.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...